慢性C型肝炎患者におけるPegasys®の臨床試験

基本情報

NCT ID: NCT00245414
ステータス: 完了
試験のフェーズ: 第4相
試験タイプ: 介入
目標被験者数: 108
治験依頼者名: Chugai Pharmaceutical

概要

The purpose of this study is to investigate the efficacy and safety of Pegasys® 180μg for subcutaneous (s.c.) injection in interferon (IFN)-treated or IFN-untreated chronic hepatitis C patients except for those infected with genotype 1b of hepatitis C virus (HCV) and a high viral load (≥ 100 KIU/mL). In addition, this study will explore the efficacy and safety of Pegasys® 180μg for s.c. injection given at 2 different periods between 24 and 48 weeks in IFN-untreated chronic hepatitis C patients.

対象疾患

Chronic Hepatitis C

介入

Pegasys®(DRUG)

依頼者（Sponsor）

中外製薬株式会社(INDUSTRY)

実施施設 (6)

Kinki Region

Osaka, Japan

Kyusyu Region

Fukuoka, Japan

Kanto Region

Tokyo, Japan

Tokai Region

Yamanashi, Japan

北海道大学病院

Sapporo, Japan

Chugoku Region

Okayama, Japan